+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Scleroderma Diagnostics and Therapeutics - Global Market Trajectory & Analytics

  • ID: 5310778
  • Report
  • April 2021
  • Region: Global
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • Bayer AG
  • Cytori Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Pfizer, Inc.
  • Sanofi SA
Global Scleroderma Diagnostics and Therapeutics Market to Reach $4 Billion by 2027

Amid the COVID-19 crisis, the global market for Scleroderma Diagnostics and Therapeutics estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$4 Billion by 2027, growing at a CAGR of 10.3% over the period 2020-2027. Localized, one of the segments analyzed in the report, is projected to record 9.5% CAGR and reach US$1.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Systemic segment is readjusted to a revised 11% CAGR for the next 7-year period.



The U.S. Market is Estimated at $598.9 Million, While China is Forecast to Grow at 9.6% CAGR

The Scleroderma Diagnostics and Therapeutics market in the U.S. is estimated at US$598.9 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$692.8 Million by the year 2027 trailing a CAGR of 9.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.4% and 8.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Select Competitors (Total 42 Featured):
  • Actelion Pharmaceuticals Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Corbus Pharmaceuticals Holdings, Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Cytori Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Pfizer, Inc.
  • Sanofi SA
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer AG
  • Cytori Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Pfizer, Inc.
  • Sanofi SA
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Scleroderma Diagnostics and Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Localized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Localized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Localized by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Systemic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Systemic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Systemic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Immunosuppressive Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Immunosuppressive Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Immunosuppressive Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 16: World Current & Future Analysis for Endothelin receptor antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 17: World Historic Review for Endothelin receptor antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 18: World 15-Year Perspective for Endothelin receptor antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 19: World Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 20: World Historic Review for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 21: World 15-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 22: World Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 23: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 24: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 25: USA Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 26: USA Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 27: USA 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
  • Table 28: USA Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 29: USA Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 30: USA 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
  • CANADA
  • Table 31: Canada Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 32: Canada Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 33: Canada 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
  • Table 34: Canada Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 35: Canada Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 36: Canada 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
  • JAPAN
  • Table 37: Japan Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 38: Japan Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 39: Japan 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
  • Table 40: Japan Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 41: Japan Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 42: Japan 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
  • CHINA
  • Table 43: China Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 44: China Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 45: China 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
  • Table 46: China Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 47: China Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 48: China 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
  • EUROPE
  • Table 49: Europe Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 50: Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 51: Europe 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 52: Europe Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 53: Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 54: Europe 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
  • Table 55: Europe Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 56: Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 57: Europe 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
  • FRANCE
  • Table 58: France Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 59: France Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 60: France 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
  • Table 61: France Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 62: France Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 63: France 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
  • GERMANY
  • Table 64: Germany Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 65: Germany Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 66: Germany 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
  • Table 67: Germany Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 68: Germany Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 69: Germany 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
  • ITALY
  • Table 70: Italy Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 71: Italy Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 72: Italy 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
  • Table 73: Italy Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 74: Italy Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 75: Italy 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
  • Table 76: UK Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 77: UK Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 78: UK 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
  • Table 79: UK Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 80: UK Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 81: UK 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
  • REST OF EUROPE
  • Table 82: Rest of Europe Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 83: Rest of Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 84: Rest of Europe 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
  • Table 85: Rest of Europe Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 86: Rest of Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 87: Rest of Europe 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
  • Table 88: Asia-Pacific Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 89: Asia-Pacific Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 90: Asia-Pacific 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
  • Table 91: Asia-Pacific Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 92: Asia-Pacific Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 93: Asia-Pacific 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
  • REST OF WORLD
  • Table 94: Rest of World Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 95: Rest of World Historic Review for Scleroderma Diagnostics and Therapeutics by Indication - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 96: Rest of World 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Indication - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2012, 2020 & 2027
  • Table 97: Rest of World Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 98: Rest of World Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 99: Rest of World 15-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers and Other Drug Classes for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 42
Note: Product cover images may vary from those shown
  • Actelion Pharmaceuticals Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Corbus Pharmaceuticals Holdings, Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Cytori Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Pfizer, Inc.
  • Sanofi SA
Note: Product cover images may vary from those shown
Adroll
adroll